Sryla P B

Sryla is a biotechnology company focused on developing next-generation oral small molecule therapies for cardiovascular and metabolic diseases. The company's lead program targets PCSK9, a well-validated regulator of LDL cholesterol levels, with the goal of providing a more convenient oral alternative to existing injectable treatments. By leveraging advanced medicinal chemistry, Sryla aims to address significant unmet needs in lipid management and atherosclerotic cardiovascular disease. The company is currently advancing its pipeline through pre-clinical development to establish a new standard of care for patients with high cholesterol.